Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue.

Bristol-Myers

Citigroup

GlaxoSmithKline

Seaboard

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), GlaxoSmithKline PLC (NYSE:GSK), Citigroup Inc. (NYSE:C) and Seaboard Corp. (SEB).

Kahn Brothers' Biggest 3rd-Quarter Sells

Merck (NYSE: MRK) — known as MSD outside the US and Canada — announced recently that it entered into a definitive agreement pursuant to which Merck (through a subsidiary) will buy all of the outstanding shares of VelosBio for $2.75 billion in cash. The post Why Merck (MRK) Is Buying VelosBio For $2.75 Billion In Cash appeared first on Pulse 2.0.

Why Merck (MRK) Is Buying VelosBio For $2.75 Billion In Cash

Merck's stock lost more than 28% – dropping from $92 at the beginning of the year to $66 in late March – then jumped 21% to around $80 now. That means it has partially recovered to the levels where it started the year.

Merck Stock Poised For 25% Gains

The cancer-focused pharmaceutical giant will buy a privately held biotech developing a potential first-in-class treatment.

Merck Makes a $2.8 Billion Bet on an Experimental New Cancer Drug

Merck early Thursday announced a $2.75 billion agreement to buy privately held VelosBio, a maker of promising drugs to treat lung, breast, lymphoma and other types of cancer; MRK stock rose. The post Merck Expands Cancer Drug Portfolio With $2.75 Billion Acquisition appeared first on Investor's Business Daily.

Merck Expands Cancer Drug Portfolio With $2.75 Billion Acquisition

Amgen

Discovery

eBay

Macerich

Pfizer

Simon Property Group

Our call of the day offers up several stocks that busy, distracted investors have been overlooking. Smead Capital Management's CIO says they are stocks to hold for the long run.

Need to Know: These 7 unloved stocks are for the long haul, says contrarian manager

RESEARCH TRIANGLE PARK, N.C., Nov. 5, 2020 /PRNewswire/ -- Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive agreement to be acquired by...

Pappas Capital Portfolio Company VelosBio to be Acquired by Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA12-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shares of Merck & Co. Inc. rose 1.0% in premarket trading Thursday, after the drug maker announced a deal to buy privately held biopharmaceutical company VelosBio Inc. for $2.75 billion in cash. The deal is expected to close by the end of 2020.

Merck to buy VelosBio for $2.75 billion to bolster oncology pipeline

KENILWORTH, N.J. & SAN DIEGO--(BUSINESS WIRE)---- $MRK #MRK--Merck to Acquire VelosBio

Merck to Acquire VelosBio

PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, today announced an additional collaboration agreement in AI for new drug design with Merck KGaA, Darmstadt, Germany, a leading science and technology company. In this new collaboration, Iktos' de novo generative design technology will be used in a structure-enabled context to facilitate the rapid and cost-effective design of an undisclosed Merck KGaA, Darmstadt, Germany drug discovery progr

Iktos Announces Additional Collaboration With Merck KGaA, Darmstadt, Germany in AI for New Drug Design

The founder and former CEO of Seattle health tech startup Navigating Cancer, Gena Cook, is suing one of the company's investors, pharmaceutical giant Merck's Global Health Innovation Fund, on claims including gender discrimination, wrongful termination, and blocking a potential acquisition of the startup by one of Merck's rivals.

Navigating Cancer's founder and former CEO sues its investor Merck, alleging gender bias and interference with acquisition talks

Anthem

Biogen

Cigna

Johnson & Johnson

Eli Lilly

UnitedHealth Group

Shares of UnitedHealth Group Inc. soared 10.2% in morning trading, enough to pace the Dow Jones Industrial Average's gainers, as the uncertain election outcome is seen as a boon to the health care sector. The stock's price gain of $32.65 was adding about 215 points to the Dow's price, while the Dow was up 547 points, or 2.0%.

Health care stocks soar, add more than 350 points to the Dow's price

Merck stock has slipped this year amid the coronavirus pandemic. But the pharmaceutical company is pursuing two coronavirus vaccines.

Merck Is Pursuing Two Coronavirus Vaccines — Is Merck Stock A Buy?

Veeva Systems

BARCELONA, Spain--(BUSINESS WIRE)-- #CommercialExcellence--Chief digital officer at Almirall and CIO of healthcare at Merck KGaA, Darmstadt, Germany are featured keynote speakers at Veeva Summit Online, Europe

Digital Leaders from Almirall and Merck KGaA, Darmstadt, Germany to Keynote Veeva Summit Online, Europe

Boeing

Cisco Systems

Chevron

Dow Inc

Goldman Sachs

Intel

JPMorgan Chase & Co

Coca-Cola

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration."- DowJones&Co. 30 Dow stocks represent nine of 11 sectors. Dow tracks utilities as a separate index and omits real estate. Broker top 10 target estimated net gains ranged from 22.21%-47.29% topped by CVX 10/29/20.

4 Dogs Of The Dow Break Out And 3 Break Down In November

Merck CEO Kenneth Frazier told CNBC on Thursday that people will still have to practice mask wearing and social distancing "for the foreseeable future."

Merck CEO says Covid vaccine won't be a 'silver bullet,' predicts mask use for the 'forseable future'

Caterpillar

The earnings reports coming out of Dow components were positive, but that wasn't enough to overcome pandemic fears.

Dow Jones Doesn't Get Lift From Merck, Caterpillar, and 3M Earnings Beats

Merck & Co., Inc.'s (MRK) CEO Ken Frazier on Q3 2020 Results - Earnings Call Transcript

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc.

Do Merck and Pfizer Earnings Signal a Pullback in Health Care?

Advanced Micro Devices

Markets are up in early trading today, even though a congressional stimulus package looks kaput.

Markets Buoy on Durable Goods, Q3 Earnings: MRK, CAT, MMM, AMD

Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.

Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance

Merck (MRK) delivered earnings and revenue surprises of 20.83% and 2.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Merck Stock (MRK)